Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech files provisional patent for Ampligen as a potential early-onset intranasal therapy
11:09am, Monday, 27'th Sep 2021
AIM ImmunoTech Inc said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy. This therapeutic use is designed to enhance and expand infection-i
OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranas
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
03:28pm, Tuesday, 21'st Sep 2021
AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive Dysfunction (PCCD). The meeting requ
AIM ImmunoTech advances bid to study Ampligen as therapy for Post-COVID-19 Cognitive Dysfunction
09:05am, Tuesday, 21'st Sep 2021
AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) - a new and serious c
OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (
AIM ImmunoTech offers a status update on its pending Phase 2a Human Challenge Trial using its flagship drug Ampligen
10:29am, Monday, 20'th Sep 2021
AIM ImmunoTech Inc. provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic therapy using a human rhino
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen
09:15am, Monday, 20'th Sep 2021
OCALA, Fla., Sept. 20, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen
AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
12:22pm, Wednesday, 08'th Sep 2021
AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cogni
AIM ImmunoTech Inc. said it has submitted a pre-Investigational New Drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential inf
OCALA, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and
AIM ImmunoTech files provisional patent application for use of Ampligen in Post-COVID-19 Cognitive Dysfunction
10:09am, Wednesday, 25'th Aug 2021
AIM ImmunoTech Inc has announced a new provisional patent application for its flagship drug candidate Ampligen as both an intranasal and an intravenous therapy for what the company describes as Post-C
AIM ImmunoTech is well positioned with $57.3M to advance clinical trials of flagship drug Ampligen
03:35pm, Tuesday, 17'th Aug 2021
AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corpor
AIM ImmunoTech is well positioned with $57.3M to advance clinical trials of Ampligen as cancer, coronavirus treatment
03:33pm, Tuesday, 17'th Aug 2021
AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corpor
AIM ImmunoTech is well positioned with $57.3M to execute on its corporate strategy and advance clinical trials
01:35pm, Tuesday, 17'th Aug 2021
AIM ImmunoTech Inc posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strateg
AIM ImmunoTech Provides Second Quarter 2021 Business Update
09:00am, Tuesday, 17'th Aug 2021
OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.
